Democratic Republic of Congo vs South Africa: Access to anti-retroviral drugs, male (%)
Democratic Republic of Congo
75.0%
in 2024
South Africa
75.0%
in 2024
Democratic Republic of Congo rank
55th
South Africa rank
55th
Access to anti-retroviral drugs, male (%) over time
- Democratic Republic of Congo
- South Africa
How they compare
Democratic Republic of Congo currently reports 75.0% against 75.0% in South Africa, a difference of 0.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was South Africa ahead.
Democratic Republic of Congo ranks 55th and South Africa ranks 55th of 141 countries.
South Africa has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Democratic Republic of Congo | South Africa | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.9% | 4.4% | 2.5% | South Africa |
| 2010s | 19.5% | 45.1% | 25.6% | South Africa |
| 2020s | 68.0% | 71.6% | 3.6% | South Africa |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Democratic Republic of Congo or South Africa?
- Democratic Republic of Congo, at 75.0% against 75.0% in South Africa as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Democratic Republic of Congo and South Africa?
- 0.0%, with Democratic Republic of Congo ahead.
- How many years of comparable data are there for Democratic Republic of Congo and South Africa?
- 25 years are reported by both, from 2000 to 2024.
- How do Democratic Republic of Congo and South Africa rank globally for access to anti-retroviral drugs, male?
- Democratic Republic of Congo ranks 55th and South Africa ranks 55th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.